|
|
 Lung Cancer |
 |
|
|
|
|
|
| (Page 1 of 19) « Back | 1 | 2 | 3 | 4 | 5 | Next » |
»
Vitamin supplements do not protect against lung cancer, study says
|
|
Vitamin supplements do not protect against lung cancer, according to a study of more than 77,000 vitamin users. In fact, some supplements may even increase the risk of developing it.
|
»
Bc12 protein could be a target for drug development
|
|
A protein that helps lung cancer cells thrive appears to do so by blocking healthy cells' ability to fix themselves when radiation or chemicals such as nicotine damage their DNA, according to a University of Florida study to be published Feb. 29 in the journal Molecular Cell.
|
»
New technique Provides Highly Accurate Means in finding malignant lymph nodes
|
|
Using two different endoscopes together is better than using one to stage lung cancer, and is also much more precise and less invasive than the surgical method now most commonly used, researchers at Mayo Clinic in Jacksonville, Fla., report. This new technique, which uses two small flexible tubes, one of which is inserted into a patient's esophagus to access lymph nodes in the back of the lungs while the other is placed into the trachea, or airway, to reach nodes at the front and sides, was 93 percent accurate in finding malignant lymph nodes in a group of 138 patients. This is substantially more precise than all other lung cancer staging methods now in use today, say the researchers, who tested three different methods of non-invasive staging in their study.
|
»
Vaccine Booster Gives Persistent Immune Response for lung cancer recurrence
|
|
What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years? This concept may no longer be a fantasy. In a clinical study a team headed by the international Ludwig Institute for Cancer Research (LICR) has shown that a vaccine against a protein found in cancer cells produces an immune response that can be boosted and strengthened with additional vaccine shots. Patients with resected non-small cell lung cancer (NSCLC) were treated with this investigational agent, also known as an Antigen-Specific Cancer Immunotherapeutic (ASCI), in another clinical study conducted by GlaxoSmithKline. The results showed a reduction in risk of cancer recurrence in these patients, a finding that prompted GlaxoSmithKline to initiate the largest ever clinical trial in lung cancer (MAGRIT study).
|
»
Lung Cancer Patient Response To Therapy Predicted by New Discovered Biomarkers
|
|
Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.
|
|
| (Page 1 of 19) « Back | 1 | 2 | 3 | 4 | 5 | Next » |
|
